A view from the Center

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

The future of drug rebates: Are they to be or not to be?

by George Van Antwerp, Managing Director, Deloitte Consulting LLP

Nearly half of all Americans (49 percent) have at least one prescription drug, and 12 percent of the population has five or more, according to 2017 data from the Centers for Drug Control and Prevention (CDC). In 2016, $329 billion was spent on prescription drugs—an increase of nearly 30 percent from 2010.1

With so much money at stake,

Read more

The good, the bad, and the ugly of opioids: For large employers, the epidemic can stretch far beyond medical claims

by George Van Antwerp, Managing Director, Deloitte Consulting LLP

First the good news. While we are in the midst of an opioid epidemic, large employers have seen prescription rates fall significantly since peaking in 2009. That year, 17.3 percent of covered employees or dependents had at least one opioid prescription. People who work for large employers are now using fewer prescription opioids.1 This is likely due to an increased focus—among health plans and clinicians—on limiting opioid prescriptions among patients who might be at risk for opioid dependence.

Read more

Five barriers that could keep biosimilar manufacturers from cracking the US market

by James Forsyth, Director, Deloitte MCS Limited, and Cameron McClearn, Principal, Deloitte Consulting LLP

The biosimilars market in the US has lagged well behind the European market for more than a decade.1 While a recent push from the White House could help expand the use of biosimilars in the US, manufacturers could still face some significant challenges there.

In April, the administration released its “blueprint” for lowering drug prices and reducing out-of-pocket costs for US consumers.

Read more

The president’s executive order on health care: Not repeal, but is it a big deal?

by Anne Phelps, Principal, US Health Care Regulatory Leader, Deloitte & Touche LLP

On October 12, the White House issued an executive order directing the Departments of Health and Human Services (HHS), Treasury and Labor to consider promulgating new rules – or reinterpret existing ones – to affect the small group and individual insurance markets with the stated goal of expanding consumer choices. Since its release, quite a bit of information (and some misinformation) has come out about the order’s potential impact on the markets.

Read more

FDA releases plan to fund Innovation Account

by Doug Beaudoin, Principal, Deloitte Consulting LLP

On July 7, the FDA released its Work Plan and Proposed Funding Allocations of the FDA Innovation Account, the agency’s plan to spend the $500 million in new funding provided by the 21st Century Cures Act. The Cures Act, bipartisan legislation that became law in December 2016, allocates $6.3 billion to advance biomedical innovation by funding basic science research and allowing for innovation and flexibility for product regulation at the FDA.

Read more

Fixing health care’s affordability crisis – Let’s win this one for the Gipper!

by Bill Copeland, Vice Chairman, US Life Sciences & Health Care Industry Leader, Deloitte LLP

As of last week, my youngest daughter has her driver’s license, and we are now in the market for a car. Grace knows that, while she will be driving the car, I am the one paying for it. That gives me some special rights to set spending limits, and require certain performance elements – such as safety,

Read more